NICODERM CQ 21 mg/24h (Nicotine PATCH, EXTENDED RELEASE) 21 mg/24h

Nicoderm CQ 21 mg/24h is a transdermal patch designed to help manage nicotine dependence. This extended-release patch delivers nicotine steadily over 24 hours, supporting smoking cessation efforts.

Strength

21 mg/24h

Pack Size

14 PATCH in 1 CARTON (0135-0194-02) / 24 h in 1 PATCH

Manufacturer / TM Owner

Haleon US Holdings LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Nicoderm CQ 21 mg/24h is used as an aid to quit smoking. The patch provides a controlled release of nicotine, helping to reduce withdrawal symptoms and cravings. It is typically part of a comprehensive smoking cessation program that may include behavioral therapy and support.

Side Effects

Common effects of using Nicoderm CQ 21 mg/24h may include skin irritation at the application site, headaches, or insomnia. Some users may experience dizziness or nausea. These effects are generally mild and temporary.

Precautions & Warnings

Handle Nicoderm CQ 21 mg/24h patches carefully to avoid accidental exposure to children or pets. Apply the patch to clean, dry skin and avoid contact with water or excessive heat. Consult a healthcare provider before use if you have any medical conditions or are taking other medications.

Avoid Interactions

Nicoderm CQ 21 mg/24h may interact with certain medications, including those metabolized by the liver's CYP450 enzymes. Avoid using other nicotine products simultaneously to prevent excessive nicotine intake. Alcohol consumption should be moderated as it may affect the patch's adherence and absorption.

Frequently Asked Questions

Nicoderm CQ 21 mg/24h is used to help people quit smoking by providing a controlled release of nicotine through a transdermal patch.

The patch delivers nicotine steadily through the skin over 24 hours, helping to reduce withdrawal symptoms and cravings associated with quitting smoking.

If you have skin allergies, consult a healthcare provider before using Nicoderm CQ 21 mg/24h, as the patch may cause skin irritation.

Store Nicoderm CQ 21 mg/24h patches at room temperature, away from moisture and heat, and keep them out of reach of children.

If you experience side effects, such as skin irritation or headaches, consult a healthcare provider for advice on managing these effects.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.